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ABSTRACT: The development of smart targeted nanoparticles (NPs) that can identify
and deliver drugs at a sustained rate directly to cancer cells may provide better effi-
cacy and lower toxicity for treating primary and advanced metastatic tumors. Obtain-
ing knowledge of the diseases at the molecular level can facilitate the identification
of biological targets. In particular, carbohydrate-mediated molecular recognitions us-
ing nano-vehicles are likely to increasingly affect cancer treatment methods, opening a
new area in biomedical applications. Here, silicon NPs (SiNPs) capped with carbohy-
drates including galactose, glucose, mannose, and lactose have been successfully syn-
thesized from amine terminated SiNPs. The MTT analysis shows an extensive reduc-
tion in toxicity of SiNPs by functionalizing with carbohydrate moiety both in vitro and
in vivo. Cellular uptake has been investigated with flow cytometry and confocal fluo-
rescence microscope. The results show the carbohydrate capped SiNPs can be inter-
nalized in the cells within 24 h of incubation, and can be taken up more readily by
cancer cells than noncancerous cells. Moreover, these results reinforce the use of car-
bohydrates for the internalization of a variety of similar compounds into cancer cells. Q1
1. Introduction
Every year, millions of people’s lives worldwide are affected
by a complex group of diseases known as cancer. Even though
traditional chemotherapies that indiscriminately act against ac-
tively dividing cells have been identified as one of the most
effective methods of cancer therapy, chemotherapeutic agents
exhibit poor specificity in reaching tumor tissue and are of-
ten restricted by dose-limiting toxicity. To overcome these ma-
jor drawback of chemotherapy, targeted drug delivery, and
controlled drug release technology may provide a more effi-
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cient and less harmful solution, as targeted therapies specifi-
cally interfere with those molecules essential for tumor growth
and progression.[1] Targeted therapies include monoclonal an-
tibodies and small molecule inhibitors targeting tumor spe-
cific markers. It is well known that tumors express particular
molecular signatures that discriminate them from healthy tis-
sues, providing a rich source of potential targets. However,
there are some methodological weakness to this general ap-
proach. For example, the identification of tumor specific mark-
ers is a time consuming process. validating any application
requires that patients must be stratified prior to treatment to
ensure that the appropriate targets are present in each case.
As such these treatments are expensive, for example colorectal
cancer targeted therapies can cost several thousand dollars per
month.[2] Therefore, as people live longer, with accompanying
improvements in early detection rates, the financial burden
of providing targeted cancer therapies is expected to rise sub-
stantially. Furthermore, tumor cells have high tendencies to
mutate, which changes their antigenic modifications leading
to negative results. A good example of this is the multiple re-
sistance mechanisms observed in targeting the constitutively
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active, pro-proliferative BrafV600E mutation in melanoma.[3–9]
A possible alternative to tumor-specific targeting using over-
expressed oncogenes is to take advantage of other molecules
present on the surface of cells, such as cell surface carbohy-
drates.
Carbohydrates are attractive targets for receptor–mediated
interaction and in particular glycol-conjugates, which play im-
portant roles in cancer development metastasis. Many types
of mammalian cells are covered with a dense layer of carbo-
hydrates known as the glycol-calyx, in which carbohydrates
are bound to proteins and lipids to form glycoproteins, pro-
teoglycans, and glycolipids. These naturally occurring glycol-
conjugates play an important role in the process of cell–
cell interactions and cell–cell communication that is vital for
physiological and pathological processes.[10, 11] As one of the
most common cell–surface ligands, carbohydrates can direct
the initiation of many medicinally important physiological
processes where they are involved in a wide variety of cel-
lular events,[12–14] including inflammatory and immunologi-
cal responses,[15–17] tumor metastasis,[18] cell–cell signaling,[19]
apoptosis, adhesion,[20] bacterial and viral recognition,[20, 21] and
anticoagulation.[22]
The biological roles of carbohydrates as signaling effectors
and recognition markers are associated with specific molecular
recognition in which proteins[23] or other carbohydrates[24] are
involved. This characteristic led to the identification of tumor-
associated carbohydrate molecules,[19, 25] which has greatly im-
proved the development of carbohydrate-based anticancer vac-
cine studies.[26] However, the understanding of carbohydrate-
binding properties of tumors is not well defined. Cancer cells
can interact with the extracellular matrix in their microenvi-
ronment through endogenous receptors binding with cognate
carbohydrates.[26, 27] These interactions vary, depending on the
physiological state of the cells, as supported by histological stud-
ies of tumor tissues.[28, 29] Therefore, the ability to characterize
and distinguish carbohydrate binding profiles of a variety of
cells can expedite both the mechanistic understanding of their
role in disease development and the expansion of diagnostic
and therapeutic tools.[30–32]
When nanoparticles (NPs) are functionalized with ligands
such as antibodies, proteins or peptides, oligonucleotides or
carbohydrates, they become excellent vehicles for biological
applications at the cellular and molecular level.[33] However,
several features need to be fine-tuned including ligand den-
sity, particle diameter, surface charges, magnetic, electronic or
optical properties, stability, and targeting specificity. Nanoma-
terials can serve as promising platforms for displaying carbo-
hydrates for biological recognition. Due to the smaller sizes
of NPs compared to their micrometer sized counterparts, NPs
have much larger surface areas, which can enable higher ca-
pacity in receptor binding. In addition, multiple carbohydrate
ligands can be immobilized onto one NP, which can poten-
tially enhance the weak affinities of individual ligands to their
binding partners.
Silicon NPs (SiNPs) hold prominent interest in various
fields of biomedical research including imaging, detection,
sensing to drug delivery and new therapeutic uses for a vari-
ety of diseases including cancer.[34, 35] This is in addition to the
electronic, magnetic, and optical properties exhibited by these
NPs. SiNPs or quantum dots have size dependent tuneable
light emission, bright luminescence and stability against pho-
tobleaching compared to organic fluorescent dye molecules,
which makes them ideal tools for fluorescence imaging. All
these properties have enabled SiNPs to be used as fluorescent
cellular markers in a number of diagnostic and assay roles.[36, 37]
Moreover, when comparing with heavy metal and other types
of semiconductor quantum dots, SiNPs exhibit low inherent
toxicity.[37–40]
Herein, we explore the possibility of using glyco-conjugated
SiNPs to detect various cancer cell types on the basis of the more
physiologically related carbohydrate–receptor interactions. We
have focused on SiNPs functionalized with carbohydrates that
play key roles in molecular recognition processes, rather than
those where carbohydrates mainly function as NP stabilizing
agents.[41–43] The information obtained on the physiologically
relevant carbohydrate–receptor interaction will not only en-
hance our understanding of the role carbohydrates play in can-
cer, but also guide the development of potential therapeutics
such as novel contrast agents for tumor detection.
2. Results and Discussions
2.1. Stability of Carbohydrate Capped SiNPs in Biological
Media
A significant challenge in the use of NPs for biomedical ap-
plications is to retain their stability in biologically associated
environments. In order to achieve this, NPs have to be hy-
drophilic and maintain superior stability in biological media.
For advanced biomedical applications of NPs (e.g., in vivo di-
agnostics and therapy), additional requirements such as mini-
mization of nonspecific uptake by reticuloendothelial systems
must be imposed in order to achieve long blood circulation
time and high diagnostic or therapeutic efficiency.[44] To in-
vestigate the in vivo effects of NPs in the circulation, and to
measure the effects of NPs on different cell types in vitro, NPs
have to be dispersed in physiological solutions. However, parti-
cles which are dispersed in solutions containing physiological
salt concentrations and pH values can form micrometer-sized
coarse agglomerates.[45–47] Coarse agglomerates of NPs have
been shown to exert different biological effects compared to
well-dispersed nanoparticles.[48–50] Moreover, aggregation can
induce toxicity both in vitro and in vivo models.[51] Therefore,
it is important to investigate the effect of biological media on
carbohydrate capped SiNPs.
Dynamic light scattering (DLS) was used to assess the stabil-
ity of carbohydrate capped SiNPs in biological media by mon-
itoring the variation of the average hydrodynamic size of the
NPs. For long-term stability testing, 0.1 mL solution of carbohy-
drate capped SiNPs was incubated in 1 mL of Dulbecco’s mod-
ified eagle’s medium (DMEM) with 10% FBS, Roswell Park
Memorial Institute (RPMI) with 10% FBS and 0.1 X Marc’s
Modified Ringers (MMR) as a function of time. The average
hydrodynamic diameter was measured at various time points.
Figure S1, Supporting Information, and Table 1 show the sta-
bility of carbohydrate capped SiNPs by DLS in DMEM, RPMI,
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Table 1. Diameter of carbohydrate capped SiNPs by DLS in DMEM, RPMI, and MMR media.
Carbohydrate
capped SiNPs
DMEM media DLS size[nm] RPMI media DLS size[nm] MMR media DLS size[nm]
6 h 12 h 24 h 24 h 6 h 12 h 24 h Initial 24 h
Gal SiNPs 10 ± 1.0 10 ± 1.0 15 ± 1.5 10 ± 1.0 10 ± 1.0 16 ± 1.0 37 ± 3.0 58 ± 5.0
Man SiNPs 11± 1.0 13 ± 1.0 14 ± 1.0 11 ± 1.0 15 ± 2.0 20 ± 1.0 20 ± 1.5 43 ± 3.0
Glu SiNPs 13± 1.0 13 ± 1.0 13 ± 1.0 14 ± 1.0 16 ± 1.0 16 ± 1.0 15 ± 1.5 72 ± 5.0
Lac SiNPs 14± 1.5 14 ± 1.5 16 ± 1.0 14 ± 1.0 15 ± 1.0 15 ± 1.0 38 ± 4.0 43 ± 5.0
and MMR media for various time points such as 6, 12, and 24
h.
Table 1 shows that there is no large aggregation of carbo-
hydrate capped SiNPs upon incubation with DMEM media.
The gal capped SiNPs (Figure S1a, Supporting Information)
show a slight broadening of the peak after 6 and 12 h, but the
peak position does not change. After 24 h the peak position
shifts slightly, but the overall results do not show any aggre-
gation in DMEM media. The man, glu, and lac capped SiNPs
are also very stable in DMEM media. The carbohydrate capped
SiNPs were also incubated in RPMI media for various time
points shown in Figure S2, Supporting Information,. The gal
capped SiNPs (Figure S2a, Supporting Information) did not
show any aggregation for 6 and 12 h but the peak position
shifted slightly after 24 h, which suggests that slight aggre-
gation occurred. Similarly slight aggregation was observed in
man capped SiNPs (Figure S2b, Supporting Information) after
24 h. The glu and lac-capped SiNPs were moderately stable and
did not show any sign of aggregation.
Carbohydrate capped SiNPs were also analysed in 0.1X
MMR salt buffer used to culture the X. laevis embryos. The NPs
were incubated in MMR and the DLS spectra were obtained af-
ter adding the sample and incubating for 24 h. Figure S3 of
the Supporting Information shows the DLS size distribution of
carbohydrate capped SiNPs in MMR media and it is clear that
carbohydrate capped SiNPs show some extent of aggregation
in MMR media. The size of gal capped SiNPs (Figure S3a, Sup-
porting Information) increased in MMR immediately after the
addition from around 11 nm to 37 nm (Table 1). After 24 h the
overall diameter increased up to 58 nm showing aggregation.
Man capped SiNPs did not show any significant shift at the
initial time point, but the overall diameter increased slightly
after 24 h. The glu capped SiNPs were stable after addition of
0.1X MMR, but showed aggregation after 24 h. Similarly, the
lac capped SiNPs showed an increase in size after addition,
demonstrating some extent of aggregation after 24 h.
The overall DLS stability results demonstrate that the carbo-
hydrate capped SiNPs are very stable in biological media such
as DMEM and RPMI. The main challenge of the NPs when
developing them for biological applications is that they interact
with body fluid and form an aggregation or a protein corona
around the NPs, significantly reducing their selectivity toward
the target as well as causing toxicity and affecting the final ther-
apeutic performance.[52] This is an advantage of carbohydrate
capped SiNPs as they did not interact with the protein, which
is contained in the DMEM and RPMI media, and were stable.
These stability results suggest that carbohydrate capped SiNPs
can serve as an important platform to be used for in vivo study
as well as for other biological applications.
2.2. Toxicity of Carbohydrate Capped SiNPs
2.2.1. Cytotoxicity
The effect of carbohydrate capped SiNPs on the cytotoxicity
of cells was determined by MTT assay. Potential toxicity was
examined in three cell lines: A549 (Human lung carcinoma),
HHL-5 (human immortalized hepatocytes) and MDCK (nor-
mal kidney epithelium cells). Cells were plated in 200 µL of
complete culture medium containing 50, 300, 500, 700, and
1000 µg mL−1 concentrations of carbohydrate capped SiNPs in
96-well plates for 72 h.
The results of the MTT assay, as a measure of cell viabil-
ity following 72 h exposure to carbohydrate capped SiNP, are
shown in Figure 1, with amine-terminated SiNPs as a con-
trol in the three cell lines tested. It is observed that even at a
higher particle concentration, i.e. 1000 µg/mL, cell viability is
high for all the carbohydrate capped SiNPs (often >95%) com-
pared to amine-terminated SiNPs, which induced toxicity at a
concentration of 200 µg mL−1 and above. This suggests that
the carbohydrate capping the SiNPs reduces cytotoxicity in this
concentration range. The amine-terminated SiNPs induction
of cytotoxicity at 200 µg mL−1 was confirmed by calculating
IC50 (Figure S4, Supporting Information). As one can see from
Figure 1, cell proliferation is not affected by increasing carbo-
hydrate capped SiNP concentration in all the cell lines tested,
which suggests the carbohydrate capped SiNPs did not cause
any cytotoxicity nor increased the proliferative capacity of mam-
malian cells. Furthermore, there is no effect of carbohydrate
capped SiNPs on cell morphology (Figure S5, Supporting In-
formation) supporting the finding that these NPs do not affect
cell viability. Taken together, these results strongly support the
finding that carbohydrate capped SiNPs are noncytotoxic.
2.2.2. In Vivo Toxicity Assay
To study the interaction of nanomaterials with biological sys-
tems various in vivo biological models have been proposed
which can provide a route with which to assess nanotoxicity.
Embryos are particularly sensitive indicators of adverse bio-
logical effects on the organism. Moreover, they provide a use-
ful platform to study the mechanism of action of adverse ef-
fects resulting from exposure to NPs.[53, 54] For normal embryo
development, highly coordinated cell-to-cell communications
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Figure 1. MTT analysis of carbohydrate capped SiNPs in a)
A549, b) MDCK, and c) HHL5 cell lines at various concentrations
as indicated. Error bars show standard deviation from three
independent experiments.
and molecular signaling are required; any perturbations by
nanomaterials will disrupt orderly embryogenesis leading to
abnormal development, which can manifest as morphological
malformations and embryonic death.[55]
To validate our findings that carbohydrate capped SiNPs
produce low to no cytotoxicity (Figure 1), we used X. laevis
embryos to test SiNP toxicity in vivo, X. laevis offers several
advantages as a toxicity assessment tool: large numbers of em-
bryos with each fecundation (thousands) with a very short early
development time (3 d to reach tadpole stages), external devel-
opment, close homology with human genes, and less expensive
husbandry/housing compared to small mammalian models.[56]
In this work we have used X. laevis embryos as nanotoxicity as-
sessment models for the carbohydrate capped SiNPs. Figure
Figure 2. Representative range of X. laevis embryos exposed to
carbohydrate capped SiNPs at a concentration of 200 µg mL−1
a) control, b) gal capped SiNPs, c) man capped SiNPs, d) Glu
capped SiNPs, e) Lac capped SiNPs, and f) amine-terminated
SiNPs. Embryos were exposed to the SiNPs at NF stage 15 and
scored at NF stage 38.
2 shows the images of treated X. laevis embryos. The X. lae-
vis embryos were exposed to carbohydrate capped SiNPs and
amine-terminated SiNPs at Nieuwkoop & Faber (NF) stage 15
and fixed at NF stage 38.[57] The toxicity was compared to con-
trol embryos (without NPs) shown in Figure 2a. In total 30
embryos were assessed with each NP, at three concentration
levels (50, 100, and 200 µg mL−1). They were then classified as
to what effect the SiNP treatment had: dead, presence or not of
abnormalities, common malformations (such as stunted devel-
opment, bent spine and tail, eye deformities, gut abnormalities,
edema, and blistering).
From Figure 2 it is clearly observed that carbohydrate
capped SiNPs do not induce severe toxicity in the X. laevis em-
bryos at the highest concentration of NPs tested. Lac capped
SiNPs shown to be slightly toxic by looking at tail deformi-
ties compared to that of mannose (c) and glucose (d) capped
SiNPs. Similarly, a few gal capped SiNPs exposed embryos
showed bent spine suggesting some limited toxicity. Such ob-
servations were made only at the highest concentrations tested.
In contrast, the lower concentrations did not show any mor-
phological abnormalities in X. laevis embryos for carbohydrate
capped SiNPs (Figure S6, Supporting Information). Compared
to carbohydrate capped SiNPs, amine terminated SiNPs were
shown to be highly toxic and resulted in the death of the em-
bryos as shown in Figure 2 and Figure S6, Supporting Infor-
mation. By studying both in vitro and in vivo toxicity it is clear
that the carbohydrate capped SiNPs are nontoxic in the models
tested, which highlights their strong potential for biomedical
applications.
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Figure 3. Confocal fluorescence images of A549 cells incu-
bated with gal capped SiNPs for 24 h compared to control
(without NPs). Red fluorescence from actin staining, blue from
DAPI and green fluorescence from the gal capped SiNPs.
2.3. Cellular Uptake of Carbohydrate Functionalized
SiNPs
In order to gain insights into how carbohydrate capped SiNPs
internalize within the cells, a cellular uptake experiment was
performed using confocal microscopy. Figure 3 shows the A549
cells incubated with gal capped SiNPs for 24 h compared to
control cells. Counterstaining with AlexaFlour 594-phalloidin
to stain F-actin shows that the carbohydrate capped SiNPs inter-
nalize within the cell’s cytoplasm showing green fluorescence.
Punctate green staining in the SiNPs treated cells suggests that
these nanomaterials are taken up into intracellular vesicles. Im-
ages from more mature cells are shown in Figures S7 and S8,
Supporting Information.
2.4. Cellular Uptake Kinetics
To clarify and demonstrate the importance of the functional-
ization strategy on the SiNPs cell interaction, we performed
cell uptake experiments using both cancerous and noncancer-
ous cell lines. Flow cytometry was used to semiquantitatively
measure cellular uptake of the SiNPs. The instrument gave
an accumulated intensity of the SiNPs fluorescence in 10 000
cells. Therefore, the total fluorescence of particles in one cell is
measured by this approach.[58] The carbohydrate capped SiNPs
were introduced to three cancerous cell lines (A549, MCF-7,
and SK-Mel28) and two noncancerous, immortalized cell lines
(MDCK and HHL5).
A major hurdle for cancer treatment and early cancer de-
tection is the identification of pertinent cellular signatures to
allow the differentiation of normal cells from their cancer-
ous counterparts. This could be achieved by analysis of the re-
spective cellular characteristics toward carbohydrate binding.
This phenomenon was verified by evidence from the literature
that MCF-7/Adr-res cells contain the cancer-specific galacto-
side binding galectins-4, 7, and 8, which are absent in non-
cancer cell lines.[59] The Penades group also demonstrated that
mouse melanoma cells are known to bind lactose due to the
presence of galectins on the surface.[60]
Initially, uptake efficiency of carbohydrate capped SiNPs
was measured at various time points in all cell lines (Figure 4).
Figure 4. Uptake efficiency of carbohydrate capped SiNPs in
cancer cells (A549, SK-Mel28, and MCF-7) and noncancerous
cells (MDCK, HHL5) at various incubation times a) 24, b) 48,
and c) 72 h. Collective results are normalized to untreated con-
trol cells, 24, 48, and 72 h. * indicates results are significant
different (p < 0.05), ** indicates results are highly significant
different (p < 0.01). The histograms depict the mean ± SD of
three independent experiments.
This allowed us to quantitatively measure the uptake efficiency
of carbohydrate capped SiNPs at a concentration of 200 µg
mL−1 in A549, MCF-7, SK-Mel28, MDCK, and HHL5 cells for
24, 48, and 72 h (Figure 4).
From Figure 4 it is observed that the carbohydrate capped
SiNPs are successfully taken up by both cancer and noncancer
cell lines. At 24 h, the mean number of intracellular gal, and
lac capped SiNPs for A549, MCF-7, SK-Mel28 cells significantly
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Figure 5. Time dependent uptake efficiency of carbohydrate
capped SiNPs in SK-Mel28 cells at various incubation times
of 1, 3, 6, 24, 48, and 72 h. Collective results are normalized to
untreated control cells, ** indicates results are highly significant
different (p < 0.01). Values are mean ± SD of the results from
three independent experiments.
exceeds the amount of NPs inside MDCK and HHL5 cells. It
is clear that the uptake efficiency of cancer cells is greater than
that of the normal cells. Notably, uptake of the four carbo-
hydrate capped SiNPs are significantly different in all three
cancer cell lines at all-time point (Figure 4 and Figure S9, Sup-
porting Information). This indicates there is some degree of
carbohydrates uptake selectivity among these cell lines. Based
on flow cytometry response, it is observed that the binding of
gal capped SiNPs and lac capped SiNPs in cancerous cells is
higher, suggesting that these cell lines have active galactose
and lactose receptors. SK-Mel28 cells were found to interact
with gal and lac SiNPs more efficiently. This is of special inter-
est since it is reported that melanoma cells bind to lactose, due
to the presence of galactin on the surface.[60]
Furthermore, the time dependent uptake study of the car-
bohydrate capped SiNPs was performed in SK-Mel28 cells at
various time points. The cells were exposed to the NPs at vari-
ous time points from a few hours to several days and the results
quantified by flow cytometry as shown in Figure 5.
Figure 5 shows the carbohydrate capped SiNPs were inter-
nalized within 24 h in SK-Mel28 cells, but the internalization
of NPs was found to be decreasing at 48 and 72 h. The optimal
uptake efficiency was at 24 h, the speed of which indicates re-
ceptor mediate endocytosis as a possible uptake mechanism.
After 24 h lower uptake could be due to exocytosis process,
metabolising Si to silicate, and cell division.
To further investigate the internalization mechanism of car-
bohydrate capped SiNPs we incubated the cells with the car-
bohydrate capped SiNPs at 4 and 37 ◦C. Traditionally, it has
been proposed that active transport of molecules across the
cell membrane is temperature dependent.[61] At low temper-
atures transport activity is strongly reduced, thus uptake of
molecules could be attributed to a nonspecific diffusional en-
try into the cells.[62] Effects from low temperature may affect
the binding of the ligand to specific cell receptors, the lateral
mobility of the ligand-receptor complex,[63] the formation of
necks in the clathrin coated pits,[64] and/or the transport of
Figure 6. Uptake efficiency of carbohydrate capped SiNPs in
SK-Mel28 cell line at a) 4 ◦C and b) 37 ◦C: Control – black, gal
– red, man – orange, glu – purple, lac – green at concentration
of 200 µg mL−1; c) Uptake efficiency of carbohydrate capped
SiNPs in SK-Mel cells at 4 ◦C (blue) and 37 ◦C (red), presented
as normalized to untreated control cells. Values are mean± SD
of the results from three independent experiments.
endocytosed material from endosomes to lysosomes.[65] Endo-
cytosis of ligands such as transferrin, cholera toxin or some
viruses has been shown to be temperature dependent,[66–68] as
the ligands are able to attach to cell membranes at low tem-
peratures, but not internalized. Recent work has shown uptake
is energy dependant.[69–71] Based on this concept, carbohydrate
capped SiNPs were incubated with the SK-Mel28 cells at low
and normal incubation temperatures, and SiNP uptake ana-
lyzed using flow cytometry analysis (Figure 6). From Figure 6
it is clearly observed that the SiNPs incubated with cells at 37
◦C were internalized, while the flow cytometry signals were at
a significantly lower level for those incubated at 4 ◦C. There-
fore, the obtained results suggest that the cellular uptake of
carbohydrate capped SiNPs is likely to be energy dependent,
suggesting it could be receptor-mediated.[72]
3. Conclusion
Our findings suggest that carbohydrate capped SiNPs could be
useful tumor detection agents. These NPs proved to be very
stable in biological media, shown by DLS measurements. The
minimal toxicity of carbohydrate capped SiNPs was confirmed
using both in vitro and in vivo models. The in vitro toxicity was
verified by MTT assay in three types of mammalian cell lines.
The carbohydrate capped SiNPs were found to have no signifi-
cant toxicity at the highest concentration of 1000 µg mL−1. The
in vivo toxicity of carbohydrate capped SiNPs was examined
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in X. laevis embryos; the SiNPs were shown to be nontoxic for
embryos up to 200 µg mL−1 and no death or morphological
damage was observed. The results were compared with amine-
terminated SiNPs, which were as expected highly toxic and
resulted in the death of embryos. The obtained results sug-
gest that the SiNPs are uniformly capped with carbohydrate
molecules, which make them stable as well as nontoxic in both
in vivo and in vitro models.
The uptake efficiency of carbohydrate capped SiNPs was
quantified by flow cytometry. The obtained results indicated
that carbohydrate capped SiNPs internalize in the cell within
24 h. The fluorescence uptake of carbohydrate capped SiNPs
was quantified in both cancer and noncancerous cell lines and
the cancerous cells more readily took up carbohydrate capped
SiNPs than noncancerous lines, which is important in terms
of developing future diagnostic tools or even drug delivery sys-
tems to tumors. The uptake of carbohydrate capped SiNPs was
visualized by fluorescence and confocal microscopy. The NPs
showed quick accumulation inside the cancer cells.
Our understanding of cancer cell functions, such as endocy-
tosis, cell–matrix and cell–cell communications, can be greatly
enhanced by studying carbohydrate–receptor functions as a re-
sult of carbohydrate capped SiNP utilization. In addition, such
studies can help further understanding of specificity and ligand
optimization, and exploitation of carbohydrate capped SiNPs
for in vivo cancer detection.
4. Experimental Section
Synthesis of Carbohydrate capped SiNPs: Carbohydrate capped
SiNPs were synthesized from amine-terminated SiNPs using
a previously described method.[73, 74] The acid functionalized
carbohydrate derivatives (gal, man, glu, and lac) were syn-
thesized according to the literature, followed by the isolation
of pure anomers (detailed synthesis is presented in the sup-
porting document). The gal, man, glu, and lac capped SiNPs
were synthesized using their corresponding pyranosyl acid. A
pyranosyl acid galactose, mannose, glucose, and lactose (30
mg, 0.078 mmol) and 1-ethyl-3-(3-dimethylaminopropyl) car-
bodiimide (EDC 14 mg, 1 equiv, 0.085 mmol) were dissolved
in dichloromethane (5 mL) and left with stirring for 2 h at
room temperature. After 2 h N-hydroxysuccinimide (NHS) and
freshly prepared amine-terminated SiNPs were dissolved in
methanol and added into the reaction mixture. The reaction
was stirred for 24 h at room temperature (Scheme 1).
In order to remove the unreacted amine-terminated SiNPs,
the crude reaction mixture was washed three times with water
(3× 10 mL) and extracted into CH2Cl2. The mixture was dried
with Na2SO4, and solvent was removed under vacuum. After
washing, the reaction mixture was further ensued for deacety-
lation. Deacetylation of carbohydrate capped SiNPs was per-
formed with sodium methoxide in methanol and then stirred
for 30 min with Dowex 50W-X8 [H+]c resin. The byproduct urea
and impurities were difficult to remove at this stage because
both the byproduct and OAc-carbohydrate-capped SiNPs (gal,
man, glu, and lact) are soluble in dichloromethane. Deacetyla-
tion of the reaction mixture removes the acetate group of the
Scheme 1. Schematic representation of carbohydrate capped
SiNPs synthesis.
carbohydrate capped SiNPs and offers hydroxyl carbohydrate
capped SiNPs, which are soluble in water. In order to obtain a
pure product, the mixture was washed with dichloromethane to
remove impurities and urea. A pinkish solid product of the pure
carbohydrate capped SiNPs was obtained after deacetylation of
each crude reaction mixture. This sticky solid was redissolved
in water for further characterization. Physical characterisation
results of synthesized SiNPs, such as size, size distribution,
and Zeta-potential, are listed in Figures S10 and S11, Tables
S1 and S2 of the Supporting Information.
Dynamic Light Scattering (DLS): DLS measurement was
recorded with a Zetasizer Nano ZS (Malvern Instruments
Ltd., U.K.). Carbohydrate capped SiNPs were dissolved in
DMEMwith 10% FBS, RPMI medium with 10% FBS and 0.1X
Marc’s modified ringers pH7.4 (MMR; 100× 10−3 M NaCl, 2×
10−3 M KCl, 2× 10−3 M CaCl2, 1× 10
−3 M MgCl2, and 5× 10
−3
M HEPES) as a function of time. The hydrodynamic diameters
were obtained at room temperature.
Cell Culture: The human-derived hepatocyte HHL5 and
breast cancer MCF7 cell lines were a kind gift from Y. Bao,
and the immortalized kidney MDCK cell line was a kind gift
from M. Mogensen, University of East Anglia, Norwich. The
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human melanoma SK-mel28 was a kind gift from A. Chien
and R. T. Moon, University of Washington, Seattle. The lung
carcinoma A549 cell line was a kind gift from D. Sexton, Liv-
erpool John Moores University, Liverpool. All lines used were
regularly confirmed as mycoplasma free using a PCR-based
assay.[75] Cells were sub-cultured as previously described.[76]
Briefly, cells were incubated at 37 ◦C, 5% CO2/95% air and cul-
tured in RPMI (MCF7, A549) and DMEM (SK-Mel28, MDCK,
HHL5) supplemented with 10% heat-inactivated foetal bovine
serum, 2 × 10−3 M L-glutamine, 100 µg mL−1 penicillin, and
100 µg mL−1 streptomycin (all purchased from Life Technolo-
gies, Carlsbad, CA). Cells were never cultured beyond passage
30.
Cell Proliferation Assay: Cell proliferation in the presence
of carbohydrate capped SiNPs was evaluated by MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay.
Different cell lines were used in order to achieve a more com-
plete study: HHL5 (immortalized human hepatocytes), A549
(lung carcinoma cells), and MDCK (Madin Darby canine kid-
ney cells) cells were seeded in a 96-well plate for 24 h. The
cells were then treated with carbohydrate capped SiNPs (gal,
glu, man, and lac) at various concentrations (50, 300, 500, 700,
and 1000 µg mL−1) for 72 h. Afterward, normal procedure was
applied as described in the previous publication.[38] All experi-
ments were repeated on at least three different occasions.
Culturing Embryos: These experiments were performed in
compliance with institutional guidelines at the University of
East Anglia. The local ethical review committee (according to
UK Home Office regulations) has approved the research. X.
laevis embryos were obtained as previously described.[77] Em-
bryos were incubated at 18 ◦C until the required stage was
achieved according to the Nieuwkoop and Faber (NF) devel-
opmental staging system.[57] Any dead embryos were removed
throughout the culturing process. Embryos were cultured in
0.1× MMR supplemented with 25 µg mL−1 gentamycin.
Exposure to Carbohydrate Capped SiNPs: Live embryos were
collected for exposure to SiNPs at NF stage 15 to 38, as described
above. These stages of Xenopus were selected to assess NP
toxicity as they represent a key stage in development of the
embryos, through neuralation (NF stage 15), to tadpole stages
(NF stage 38). Concentrations of NPs were made up using
serial dilutions in 0.1×MMR. In a 24-well plate, 5 embryos per
well were exposed to the varying concentrations of SiNPs in
a total volume of 1000 µL per well. Embryos were incubated,
exposed to SiNPs, at 18 ◦C until the required NF stage.
Fixing Embryos: Embryos exposed to SiNPs were fixed at NF
stage 38. Fixing was carried out as previously described.[77]Once
the embryos reached the required NF stage they were washed
in 0.1×MMR and fixed in MEMFA (0.1% MOPS [pH7.4], 2 ×
10−3 M EGTA, 1× 10−3 M MgSO4, and 3.7% formaldehyde) for
1 h at room temperature. After two washes in PBS all embryos
were scored for gross phenotypic abnormalities.
Confocal Laser Scanning Microscopy (CLSM): HHL5 and
A549 cells were seeded on 12-well plates with cover slips at
a density of 3 × 104 cells per well and exposed to 150 µg
mL−1 of carbohydrate capped SiNPs for 24 h. The cell were
then washed twice by PBS and fixed by Paraformaldehyde so-
lution for 10 min. To visualize the cells, they were stained
with Lysotracker-Red (Invitrogen) or Texas Red-X Phalloidin
(Invitrogen) according to manufacturer’s protocols. Then, a
drop (approximately 2 µL) of fluorescent mounting medium
(VECTASHIELD hard, Vector Labs) was added on top of the
microscope slide. The cover slip in which cells were grown was
turned upside down on top of the mounting medium. The slide
was then dried in the fridge for ≈30 min before use. The im-
ages were taken under a confocal microscope (Zeiss LSM510
META system) using a 40X oil immersion objective lens.
Flow Cytometery: HHL5, A549, MDCK, MCF-7, and SK-
mel28 cells were seeded on 24-well plates at a density of 3
× 104 cells per well and incubated at 37 ◦C overnight. The cells
were washed with PBS and treated with 300 µg mL−1 of car-
bohydrate capped SiNPs at various time points from 1 to 72
h. Afterward, cells were harvested by trypsinization and sus-
pended in the medium (300 µL). The cellular uptake of SiNPs
was examined by Flow cytometry (Accuri C6 Flow Cytometer
System) using 380 nm excitation wavelength. A total of 10 000
events were recorded for each sample. The samples were ana-
lyzed with FlowJo Software and an average of the mean of at
least three different experiments (with different sets of NPs)
was calculated.
Supporting Information
Supporting Information is available from the Wiley Online
Library or from the author.
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